Patents by Inventor Hansjorg Toll

Hansjorg Toll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sequence variants
    Patent number: 10711276
    Abstract: Amino acid residue misincorporations are necessarily found in sequence variants at low concentrations in admixture with expressed polypeptides, resulting from one or more base mismatches within codons susceptible to amino acid residue misincorporation during transcription and/or translation. The invention provides a method of optimizing the coding sequences of a polynucleotide that encodes a polypeptide, wherein at least one codon is susceptible to amino acid residue misincorporation. The method of the invention can be used to reverse-engineer an unknown coding sequence, which encodes the same polypeptide, but differs in said at least one codon from the known coding sequence. The method can further be used to alter the immunogenic potential of an expressed polypeptide. Thus, the invention is useful in engineering optimized polynucleotides encoding polypeptides.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 14, 2020
    Assignee: Sandoz AG
    Inventors: Johann Holzmann, Michael Fuchs, Clemens Achmüller, Hansjörg Toll
  • Sequence Variants
    Publication number: 20170342422
    Abstract: Amino acid residue misincorporations are necessarily found in sequence variants at low concentrations in admixture with expressed polypeptides, resulting from one or more base mismatches within codons susceptible to amino acid residue misincorporation during transcription and/or translation. The invention provides a method of optimizing the coding sequences of a polynucleotide that encodes a polypeptide, wherein at least one codon is susceptible to amino acid residue misincorporation. The method of the invention can be used to reverse-engineer an unknown coding sequence, which encodes the same polypeptide, but differs in said at least one codon from the known coding sequence. The method can further be used to alter the immunogenic potential of an expressed polypeptide. Thus, the invention is useful in engineering optimized polynucleotides encoding polypeptides.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 30, 2017
    Applicant: Sandoz AG
    Inventors: Johann Holzmann, Michael Fuchs, Clemens Achmüller, Hansjörg Toll
  • Quantification of misfolded TNFR2:Fc
    Patent number: 9598718
    Abstract: The present invention is directed to methods for determining the relative amount of wrongly disulphide bridged TNFR2:Fc in a sample of TNFR2:Fc, a fusion protein which is used in a variety of therapeutic applications. In addition, the invention pertains to a method for purifying TNFR2:Fc using said method for determining the percentage of wrongly disulphide bridged TNFR2:Fc, and to TNFR2:Fc compositions obtained thereby.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 21, 2017
    Assignee: Sandoz AG
    Inventors: Alfred Rupprechter, Michael Fuchs, Johann Holzmann, William Lamanna, Christoph Posch, Hansjorg Toll, Robert Mayer
  • QUANTIFICATION OF MISFOLDED TNFR2:FC
    Publication number: 20160017403
    Abstract: The present invention is directed to methods for determining the relative amount of wrongly disulphide bridged TNFR2:Fc in a sample of TNFR2:Fc, a fusion protein which is used in a variety of therapeutic applications. In addition, the invention pertains to a method for purifying TNFR2:Fc using said method for determining the percentage of wrongly disulphide bridged TNFR2:Fc, and to TNFR2:Fc compositions obtained thereby.
    Type: Application
    Filed: August 8, 2014
    Publication date: January 21, 2016
    Applicant: Sandoz AG
    Inventors: Alfred Rupprechter, Michael Fuchs, Johann Holzmann, William Lamanna, Christopher Posch, Hansjorg Toll, Robert Mayer
  • Quantification of misfolded TNFR2:Fc
    Patent number: 9182410
    Abstract: The present invention is directed to methods for determining the relative amount of wrongly disulphide bridged TNFR2:Fc in a sample of TNFR2:Fc, a fusion protein which is used in a variety of therapeutic applications. In addition, the invention pertains to a method for purifying TNFR2:Fc using said method for determining the percentage of wrongly disulphide bridged TNFR2:Fc, and to TNFR2:Fc compositions obtained thereby.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: November 10, 2015
    Assignee: Sandoz AG
    Inventors: Alfred Rupprechter, Michael Fuchs, Johann Holzmann, William Lamanna, Christoph Posch, Hansjorg Toll, Robert Mayer